O'Neill Institute  |  April 2, 2024

Read the Publication

WHILE THERE IS NOW A WIDE ARRAY OF PRODUCTS available for the treatment of HIV, as well as a growing number of products for prevention, there remains a need to expand access so that the populations most vulnerable to HIV have their treatment and prevention needs met. Both HIV treatment and PrEP typically involve daily oral pills. Many people from communities most impacted by HIV, however, face challenges in taking medication daily. Innovative longer-acting (LA) products have been developed that give users alternatives to daily pill taking that offer the potential to increase adherence and persistence to medication regimens. To date, the FDA has approved LA products that only need to be administered every two months, but more products are on the horizon with likely different dosing schedules. While potentially transformative, uptake of these new LA products has been slow and efforts are needed to expand access.

Read the Quick Take here.

Related Initiatives

Infectious Diseases

Latest publications See All